AVIRON +14%?????? Grippemittel vor der Zulassung??? - 500 Beiträge pro Seite

[Lena97]

Hallo!
Wer weis mehr? Ist Aviron gestern wegen der allgemeinen guten Stimmung bei den Biotechwerten hochgegangen, oder gibt es Informationen über die Zulassung des Grippemittels?

[korkut]

sie wurden empfohlen:

FreeRealTime.com Teleconference for Year-End & RedChip Merger Announcement
Thurs., June 8, 2000, 4:30 PM(ET) Click Here to listen to Broadcast




AVIRON - NASDAQ Stock Market: AVIR
Quote, Profile, History, News, Options, Chart, Big Charts, MarketGuide, StockTalk Remove from WatchList

News June 16, 09:37 Eastern Time

The Wall Street Transcript Publishes Analyst Interview in U.S. Bancorp Piper Jaffray Conference Issue

NEW YORK, June 16, 2000 (PRIMEZONE via COMTEX) -- Thirteen leading analysts and
top management from ninety-seven sector firms examine Investing Strategies in
this special 364-page U.S. Bancorp Piper Jaffray Conference Issue from The Wall
Street Transcript (212/952-7433) or http://www.twst.com/info/info114.htm." target="_blank" rel="nofollow ugc noopener">http://www.twst.com/info/info114.htm.

1) Biotechnology Stocks - In an in-depth (3,600 words) Analyst Interview, Mark
Augustine, Senior Research Analyst with U.S. Bancorp Piper Jaffray`s Equity
Research Group, examines the outlook for the sector, including the DSL niche,
optical networking technology, mergers and acquisitions activity, and shares
specific stock recommendations.

Augustine explains his group`s approach to the biotech sector. "As with many
other sectors covered by our firm, we have decided to divide things up, and in
this case, along the lines of disease focus. I have spent considerable time over
the last 10 years in infectious disease, autoimmune/inflammatory disease, and
cardiovascular disease as well as specialty and vaccine companies. The names
that I look at in these areas are generally product-based companies."

Augustine labels MedImmune (Nasdaq: MEDI) an exciting story. "This is because
there is no competition in sight and the fact that it addresses a compelling
medical need and the company will be able to leverage its flagship product into
other patient populations, such as the elderly and the less severely premature,
and generate, we believe, a 30% sustainable earnings growth rate."

Augustine highlights Aviron (Nasdaq: AVIR). "Another approach to prevention that
stands, we believe, to be approved next year is a novel intranasal influenza
vaccine. That`s a product out of a pure-play vaccine company called Aviron in
Mountain View, California. We see a 2001 approval and launch for an important
product here that has $600 million in peak worldwide sales potential."

BioChem Pharma (Nasdaq: BCHE) is on the rebound, according to Augustine. "Zeffix
sales have begun to accelerate and BioChem Pharma, an unbelievably cheap stock,
might actually be a stock in rebound this year as Zeffix sales accelerate and
they get an interesting cancer drug, troxacitabine, through Phase II studies. We
project a 31% five-year earnings growth."

Alexion (Nasdaq: ALXN) is an exciting company, according to Augustine. "Alexion
is developing novel anti-inflammatory drugs that inhibit complement proteins. If
there is positive news in any one of these Phase II studies, we think the stock
could double. They`ve got an outstanding management team, and it`s perhaps the
most exciting earlier stage biotech company that we`re focusing people on at
this point."

This 364-page U.S. Bancorp Piper Jaffray Conference Issue also features:

2) Outlook for U.S. Bancorp Piper Jaffray - In an in-depth (1,600 words) Analyst
Interview, Thomas Schreier, Managing Director of U.S. Bancorp Piper Jaffray,
examines the outlook for the five sectors he covers, and highlights the theme of
this year`s conference.

3) IT Infrastructure - In an in-depth (1,100 words) Analyst Interview, Ashok
Kumar, Managing Director of U.S. Bancorp Piper Jaffray, examines the outlook for
the sector, including investment strategies, demand/supply issues, new
technology applications, and shares specific stock recommendations.

4) Wireless Communications Stocks - In an in-depth (2,300 words) Analyst
Interview, Samuel May, Managing Director of U.S. Bancorp Piper Jaffray, examines
the outlook for the sector, including investment strategies, sector trends, the
mobile internet, the U.S. Bancorp Piper Jaffray Wireless Index, and shares
specific stock recommendations.

5) Internet Software Infrastructure - In an in-depth (3,400 words) Analyst
Interview, Hany Nada, Managing Director of U.S. Bancorp Piper Jaffray, examines
the outlook for the sector, including e-commerce, trends on the demand side, his
valuation methodology, and shares specific stock recommendations.

6) B2B E-Commerce - In an in-depth (4,100 words) Analyst Interview, Jon Ekoniak,
Vice President with U.S. Bancorp Piper Jaffray, examines the outlook for the
sector, including e-commerce, various business models in the sector, and shares
specific stock recommendations.

7) Outlook for Electronic Commerce - In an in-depth (3,900 words) Analyst
Interview, Stephen Franco, Vice President with U.S. Bancorp Piper Jaffray,
examines the outlook for the sector, including e-commerce, online financial
services, investment trends, and shares specific stock recommendations.

8) Network Infrastructure - In an in-depth (1,800 words) Analyst Interview,
Conrad Leifur, Vice President with U.S. Bancorp Piper Jaffray, examines the
outlook for the sector, including the DSL niche, optical networking technology,
mergers and acquisitions activity, and shares specific stock recommendations.

9) Financial Business Services - In an in-depth (4,500 words) Analyst Interview,
Bradley Berning, Senior Research Analyst at U.S. Bancorp Piper Jaffray, examines
the outlook for the sector, including common characteristics of Financial
Business Services companies, investment themes or trends, and shares specific
stock recommendations.

10) Healthcare Services - In an in-depth (3,700 words) Analyst Interview,
William Bonello, Senior Research Analyst at U.S. Bancorp Piper Jaffray, examines
the outlook for the sector, including reimbursement basis for Healthcare
Services companies, trends in reimbursement, and shares specific stock
recommendations.

11) Lifestyle Retailing - In an in-depth (3,700 words) Analyst Interview,
Jeffrey Klinefelter, Senior Research Analyst at U.S. Bancorp Piper Jaffray,
explains the concept of lifestyle retailing, examines the outlook for the
sector, and shares specific stock recommendations.

12) Outlook for E-Health - In an in-depth (2,600 words) Analyst Interview, Daren
Marhula, Senior Research Analyst at U.S. Bancorp Piper Jaffray, examines the
outlook for the sector on the business-to-consumer and on the B2B side, and
shares specific stock recommendations.

13) Retail Hardlines Stocks - In an in-depth (4,000 words) Analyst Interview,
Rebecca Yarchover, Senior Research Analyst at U.S. Bancorp Piper Jaffray`s
Equity Research Group, examines the outlook for the sector, including retail
hardlines companies, consumer electronics, and shares specific stock
recommendations.

14) CEO/Company Interviews - Top management of ninety-seven sector firms examine
the outlook for their firm and the sector. Firms include:

AmeriCredit, Bridge Medical, Cintas, click2learn.com, Community First
Bankshares, Delano Technology, Equifax, Harris Interactive, HEALTHSOUTH,
IntraNet Solutions, JDS Uniphase, Layton BioScience, Lightspan, Lionbridge
Technologies, Metris Companies, Multex.com, National Discount Brokers Group,
OraPharma, RADVision Ltd., Retek, 99 Cents Only Stores, Abercrombie & Fitch
Company, ADC Telecommunications, Allos Therapeutics, Alloy Online, American
Dental Partners, American Express Company, AmeriPath, Applebee`s International,
Aspect Communications, Bluefly, C.H. Robinson Worldwide, Clarus, Coldwater
Creek, Commerce One, Confer Software, Davox, Ecolab, Electronics for Imaging,
Eloquent, ePocrates, E-Tek Dynamics, Expeditors International of Washington,
Family Dollar Stores, Fidelity National Financial, Gateway, Go2Net, Guitar
Center, H.B. Fuller Company, Hanger Orthopedic Group, Heller Financial,
HomeServices.com, Hormel Food Corp., iManage, Insight Enterprises, Interactive
Intelligence, iVillage, Landec, Liberate Technologies, LookSmart Ltd.,
Macrovision, MCK Communications, MedChannel, Media 100, Metron Technology NV,
Michael Foods, Mortgage.com, National Instruments, Natrol, Netcentives,
NETsilicon, Network Commerce, NextCard, Nu Skin Enterprises, Online Resources &
Communications, OrthAlliance, Performance Food Group, Pinnacle Systems, Primus
Telecommunications Group, Redback Networks, Regis, RehabCare Group, Restoration
Hardware, School Speciality, SelfCare.com, SimplyHealth.com, Spiegel, Splash
Technology Holdings, Starbucks, T/R Systems, TCF Financial, TMP Worldwide,
Tuesday Morning, U.S. Bancorp, Uno Restaurant, Witness Systems, Xchange.

To obtain a copy of this 364-page U.S. Bancorp Piper Jaffray Conference Issue,
call [phone] or see http://www.twst.com/info/info114.htm." target="_blank" rel="nofollow ugc noopener">http://www.twst.com/info/info114.htm.

The Wall Street Transcript is a premier weekly investment publication
interviewing market professionals for serious investors for over 37 years.

The Wall Street Transcript has launched a new free service where investors can
ask any of the above companies (or any public company) a question at
http://www.qawire.com.

The Wall Street Transcript does not endorse the views of any interviewee nor
does it make stock recommendations.


KEYWORDS: analysts, investments

CONTACT: The Wall Street Transcript,
Peter McLaughlin
[phone]
http://www.twst.com

DELIVERED BY PRIMEZONE MEDIA NETWORK 800-307-6627

Copyright (c) 2000. PrimeZone Media Network, Inc.



KEYWORD: New York, NY, US
INDUSTRY KEYWORD: 0
0
SUBJECT CODE: analysts
investments

[BrokerSteve]

Da wurden scjon KZ von 100 $ genannt !
Kurs akt: 33 $

[Lena97]

vielen dankk für die info korkut!!!! :-))))))))

[barri]

Was hat Avirondl für eine WK. bitte ?

[korkut]

WKN 905806
MfG Korkut

[korkut]

News June 23, 16:05 Eastern Time

Aviron and NIH Extend FluMist Agreement

MOUNTAIN VIEW, Calif., Jun 23, 2000 /PRNewswire via COMTEX/ -- Aviron (Nasdaq:
AVIR) today announced that it has extended its cooperative research and
development agreement (CRADA) for the development of FluMist(TM) with the
National Institute of Allergy and Infectious Diseases (NIAID) of the National
Institutes of Health (NIH) through June 2003. FluMist(TM) is Aviron`s
investigational intranasal influenza vaccine.

In March 1995, Aviron entered into a five year CRADA with the NIAID to conduct
clinical trials designed to further explore potential benefits of the
FluMist(TM) technology. Including both Aviron`s independent studies and studies
conducted cooperatively under the CRADA, Phase 1, 2 and 3 clinical trials have
been completed for FluMist(TM), generating safety and efficacy data in more than
13,000 children and adults.

"Aviron`s strong relationship with the NIH is a wonderful example of how the
public and private sectors can pool talent and resources to address a major
public health threat such as influenza," said C. Boyd Clarke, Aviron president
and chief executive officer.

Aviron intends to submit a Biologics License Application for FluMist(TM) to the
U.S. Food and Drug Administration in the fourth quarter of 2000.

Aviron is a biopharmaceutical company based in Mountain View, California,
focused on the prevention of disease through innovative vaccine technology.

Actual results may differ materially from the forward-looking statements
contained in this release. Factors that could cause actual results to differ
include, but are not limited to, failure to validate the manufacturing process,
facilities or equipment for the company`s nasal influenza vaccine, and the
assessment by regulatory agencies that the company`s future license applications
for its nasal influenza vaccine are incomplete or inadequate to approve the
product for marketing to one or more target populations. Additional information
concerning factors that could cause such a difference is contained in Aviron`s
SEC filings, including its Annual Report on Form 10-K for the year ended
December 31, 1999.

To receive an index and copies of recent press releases, call Aviron`s
News-On-Call toll-free fax service, 800-758-5804, extension 114000. Additional
information about the company can be located at http://www.aviron.com .

SOURCE Aviron


CONTACT: media or investors, John Bluth, 650-919-3716, or investors,
Fred Kurland, 650-919-6666, both of Aviron; or media, Claudette Hibbert of
Fleishman-Hillard, 212-453-2000, for Aviron
/Company News On-Call: http://www.prnewswire.com/comp/114000.html" target="_blank" rel="nofollow ugc noopener">http://www.prnewswire.com/comp/114000.html or fax,
800-758-5804, ext. 114000

URL: http://www.aviron.com
http://www.prnewswire.com

(C) 2000 PR Newswire. All rights reserved.



KEYWORD: California
INDUSTRY KEYWORD: MTC
BIO

[imspecht]

Hallo Lena97!
Du scheinst ja die Zulassung von Flu-Mist nicht abwarten zu können. Aber ich glaube im Moment entwickelt sich Aviron so gut, weil rein charttechnisch alles ziemlich gut aussieht. Insbesondere der Ausbruch aus der schon etwas länger andauernden Seitwärtsbewegung sieht top aus. (Hat sogar Förtschi in der Aktionär bemerkt.) Kurzfristiges Kursziel in der Aktionär ist 55 US$. Das ist meiner Meinung nach ziemlich übertrieben, da die Umsätze an der Nasdaq immer noch sehr niedrig sind. Erst müssen die mal anziehen, bevor wir in Kursziel 1000€-Träumen (wieder Förtschi, der steht ja auf runde Zahlen, siehe Morphosys) schweben dürfen. Oder aber deine lang ersehnte Meldung von der Zulassung kommt, aber glaube mir, ehe wir das wissen ist der Zug schon ohne uns abgefahren.
Bis dann IM Specht

[korkut]

News June 30, 07:00 Eastern Time

Clinical Testing Begins With Aviron CMV Vaccine

MOUNTAIN VIEW, Calif., Jun 30, 2000 /PRNewswire via COMTEX/ -- Aviron (Nasdaq:
AVIR) today announced the initiation of clinical testing with its vaccine
candidates to prevent infection with cytomegalovirus (CMV), the leading
infectious cause of birth defects in the United States.

A Phase 1, randomized, double-blind, placebo-controlled trial will evaluate the
safety of four live attenuated injectable vaccine candidates designed by Aviron
scientists. Investigators at the Vaccine Treatment and Evaluation Unit at Saint
Louis University are enrolling 25 healthy adults aged 18-50 who have had
previous natural exposure to CMV.

The study is being conducted by the National Institute of Allergy and Infectious
Diseases (NIAID), a component of the National Institutes of Health. The lead
investigator is Thomas Heineman, M.D., Ph.D., assistant professor of medicine at
Saint Louis University.

"Bringing our CMV vaccine into the clinic is a significant milestone for
Aviron`s research program," said C. Boyd Clarke, Aviron president and chief
executive officer. "Developing a vaccine to prevent CMV infection is consistent
with Aviron`s strategy to discover, develop, and commercialize innovative
vaccines for important diseases."

In 1999, the NIAID commissioned a report by the Institute of Medicine to help
prioritize vaccine research efforts. The report highlighted the public health
need for a CMV vaccine by designating it with the highest priority rating for
vaccine development.

CMV: Leading Cause of Birth Defects

Currently, there is no vaccine available for CMV, an infection with an estimated
annual cost of $4 billion in the United States. CMV is the most common viral
infection known to be transmitted to the fetus during pregnancy and is the
leading infectious cause of birth defects in the United States.

CMV infection is particularly dangerous to fetuses when their mothers are
exposed to the virus for the first time during pregnancy. The NIH estimates that
each year 40,000 infants contract CMV from their mothers and of these,
7,500-10,000 suffer significant birth defects including deafness and mental
retardation.

While 50-85 percent of the U.S. population has been exposed to CMV by age 40, in
most individuals with healthy immune systems, no symptoms result from CMV
infection. However, CMV can be life-threatening for immunocompromised patients,
including those with AIDS and those undergoing organ transplants or
chemotherapy.

Aviron is a biopharmaceutical company based in Mountain View, California,
focused on the prevention of disease through innovative vaccine technology.

Actual results may differ materially from the forward-looking statements
contained in this release. Factors that could cause actual results to differ
include, but are not limited to, failure of clinical trials to demonstrate
safety and efficacy, inability to manufacture the vaccine, and the assessment by
regulatory agencies that the company`s future license applications for its CMV
vaccine are incomplete or inadequate to approve the product for marketing to one
or more target populations. Additional information concerning factors that could
cause such a difference is contained in Aviron`s SEC filings, including its
Annual Report on Form 10-K for the year ended December 31, 1999.

To receive an index and copies of recent press releases, call Aviron`s
News-On-Call toll-free fax service, 800-758-5804, extension 114000. Additional
information about the company can be found at http://www.aviron.com

SOURCE Aviron

[imspecht]

So und jetzt mein Komentar zu der vorherigen netten Meldung:

Bei einem Medikament, bei dem gerade die klinischen Tests begonnen wurden, liegt die Wahrscheinlichkeit, dass es in 4-5 Jahren in den Markt eintritt bei deutlich unter 5%. Dies liegt im daran, dass das neue Medikament deutlich besser sein muss als ein vergleichbares schon am Markt erhältliches. Da es aber wohl für die beschriebene Anwendung noch kein Präperat am Markt gibt, besteht diese Gefahr nicht. Jedoch kann es auch in einem wesentlich späteren Stadium der Erprobung (1.2. oder 3.klinische Phase) zu Problemen bezüglich der Wirksamkeit oder der Verträglichkeit kommen. Deshalb wird die obige Meldung den Aktienkurs von AVIR wohl kaum beeinflussen, auch wenn es in Deutschland ein Börsenmagazin gibt, in dem mögliche Gewinne von Medikamenten in klinischen Tests gerne schon in den zukünftigen Aktienkurs eingepreist werden. Ich hatte das Glück mich mit jemandem unterhalten zu können, der sich mit der Zulassung von neuen Medikamenten in einer Firma beschäftigt, die aus einem deutsch-japanischen Joint-Venture hervorgegangen ist. Diese Person hält das oben beschriebene Vorgehen für völlig unseriös.

[BrokerSteve]

Die Zualssung dauert bei AVIRON kein fünf jahre mehr !!!!!

Aviron ist geardezu eine gigantiscge 1000% Wette. Sollte der Firma gelingen die Nasensprayimpfung dei der FDA durchzubekommen, rauscht die Aktie auf 500$. Der Markt ist ein 20 MRD. $ Markt !!!!!!

Aviron ist für 32 Euro geradezu ein Schnäppchen !

[imspecht]

Hi BrokerSteve!!!
Bezüglich der Zulassung um die es oben geht nur eins: Es geht hierbei nicht um FluMist, sondern um ein neues Präperat gegen Infektionen die bei Geburten die Mutter erkranken lassen. Bezüglich FluMist: Deine Kursziel 1000€ Geschichte ist wirklich lustig, da ich dies hier im Board mal als Spass gepostet hatte, weil ich die Geschichte mit Förtschi und Morphosys im 3Sat-Börsenspiel so lustig fand. Förtsch steht halt auf runde Zahlen. Ich hätte im Traum nicht geglaubt, das ein normal denkender Mensch(wichtige Eigenschaft wenn man in Aktien investiert!!)dies dann aufgreift und so tut als ob das ernst gemeint wäre. Sollte die Zulassung für FluMist bald kommen denke ich das sich dies auch erst in den AVIR-Zahlen in 2002 bemerkbar macht, den Du glaubst doch wohl nicht, das ich ein Medikament im kommenden Winter (remeber:Grippe!!!) verkaufen kann, wenn ich jetzt noch keine Zulassung habe. Damit wir uns nicht falsch verstehen, ich habe auch Aviron im Depot und glaube das die Aktie ein Brenner wird. Aber diese dämliche Puscherrei von Dir nervt schon ziemlich.
Trotzdem Good Luck!!!
IMSpecht

[toponshare]

AVIRON wird die FLUMIST-Zulassung bis Ende 2000 erhalten !!!

Mindestens 100 % Kursgewinn bis Jahresende.

[korkut]

wenn das so klar wäre, stünde die Aktie sicher nicht bei $ 34.
woher kommt die information?
ich denke zwar auch, daß die Zulassung jetzt endlich durchgeht,
dann wird der Kurs dies aber auch widerspiegeln.
Bis dahin bleibt Aviron ein äußerst spekulatives Investment.

MfG Korkut

[andibert]

Hallo allerseits,
ich denke auch,dass FluMist bis Ende 2000 auf dem Markt sein wird. Allerdings....
was kommt danach? Meines Wissens ist in unmittelbarer Zukunft von Aviron dann
nicht mehr allzuviel zu erwarten. Trotzdem könnte mit FluMist der Durchbruch gelingen. Wenn dabei aber irgendetwas schieflaufen sollte, sehe ich schwarz.
P.S.: Hab Aviron seinerzeit zu 15,5 gekauft (hähähähä)

[akaimemo]

hallo freunde von aviron,
hat zufällig jemand eine ahnung warum aviron mit 8% im plus geschlossen hat???

[alexklick]

Aviron will im 3. Quartal die Zulassung beantragen.
Sie sind das letzte mal gescheiter, weil sie nicht das richtige Herstellungsverfahren hatten um in die Produktion zu gehen. Flumist funzt also.
Das Grippemittel wird aber erst zur Grippesaison (Herbst) 2001
auf dem Markt sein.
Als kleine Info noch : Die BBBiotech AG ist an Aviron beteiligt.
Auf dieser Homepage bekommt ihr auch Infos in deutsch.

[korkut]

zusätzlich zur guten Biotech-Stimmung gab es neue FLUMIST-Fantasien


Morning Comments from SG Cowen
8/24/00
Source: SG Cowen
San Francisco, CA, August 24, 2000 8:45 PST
Baxter International - Strong Buy
Analyst/investor mtg lifts stock to new all-time high. Approval for second Recombinate suite in Thousand Oaks expected any day, but mgt does not believe Q3 results are at risk if this approval does not arrive before 9/30. Mgt also confident that it can reach its 10% sales growth target this year even if currency translations remain a stiff headwind. BAX and Strong Buy Abbott Labs our top large-cap med tech picks. BAX $82/ABT $42



Integrated Device Technology - Strong Buy
FQ2 tracking well. Appears to be on track for 15% Q/Q rev and 20% Q/Q EPS growth. At least one-third of the growth is from price increases, which fall directly to pretax profit line. SRAM mkt is at least as strong as expected. Expect strong pricing environment to continue into C2001. Reduction in cell phone handset forecast has not had much impact on DRAM, SRAM, or Flash memory mkts. Price target $100. IDTI $77

Intersil - Strong Buy
Conf call should allay investor concerns. Mgt clarified many issues surrounding wireless networks and denied speculation that Bluetooth-based products would severely degrade the performance of 802.11b-based wireless networks, such as those using ISIL`s PRISM chipsets. In fact, ISIL bought an equity stake in Silicon Wave, a closely held Bluetooth developer. ISIL still expects PRISM demand to exceed the 50% growth it experienced last Q. ISIL $51

Biotech
Buy oppys and milestones. Strong Buy Cephalon down yesterday on speculation that it falsified data for FDA. Co denies, and speculation doesn`t change the story: Prescriptions up through August, Provigil continues to grow. Co is well positioned to beat numbers for next few Qs and is our top n-t pick. Strong Buy Aviron is expected to re-file its Flumist BLA in Q4, good oppy to buy given our belief in Flumist. Strong Buy Alexion`s stock has been solid despite absence of news; however, now announced important milestone study. Completed enrollment for 200-pt rheumatoid arthritis trial. Is the first large-randomized controlled trial. Data expected in Dec, along with data for other indications. ALXN $70/AVIR $34/CEPH $48

http://www.cnetinvestor.com/yahoonews/newsitem-yahoo.asp?SYM…